Trials / Completed
CompletedNCT00743002
A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione
A Multi-center, Double-blind, Randomized, Placebo-controlled Study of TT223 in Patients With Type 2 Diabetes Treated With Metformin and/or TZD
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- OPKO Health, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is designed to show the effect of treatment with TT223 or placebo on blood glucose control after 12 weeks of treatment with a 6 month follow-up. TT223 is administered by injection once daily to patients currently treated with Metformin and/or Thiazolidinedione.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TT223 with Metformin and/or TZD | Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks |
| DRUG | Placebo with Metformin and/or TZD | Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2008-08-28
- Last updated
- 2013-06-21
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00743002. Inclusion in this directory is not an endorsement.